ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The USFDA has issued 5 observations pursuant to the completion of audit
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Subscribe To Our Newsletter & Stay Updated
